Ocular toxicity events of cyclin-dependent kinase 4/6 inhibitors in breast cancer: a pharmacovigilance study based on the faers database
{{output}}
Background: Based on the FDA Adverse Event Reporting System (FAERS) database, this study aims to explore signals of ocular-related adverse events associated with cyclin-dependent kinase 4/6 inhibitors (CDK4/6 inhibitors), providi... ...
